NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BHVN shares have decreased by 10.6% and is now trading at $35.28. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biohaven Pharmaceutical.

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Biohaven Pharmaceutical.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) posted its quarterly earnings results on Tuesday, February, 25th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by $0.94. During the same period in the prior year, the company posted ($1.34) earnings per share. View Biohaven Pharmaceutical's earnings history.

12 Wall Street analysts have issued twelve-month price objectives for Biohaven Pharmaceutical's shares. Their forecasts range from $50.00 to $100.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $70.36 in the next twelve months. This suggests a possible upside of 99.4% from the stock's current price. View analysts' price targets for Biohaven Pharmaceutical.

News articles about BHVN stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutBiohaven Pharmaceutical.

Some companies that are related to Biohaven Pharmaceutical include Beigene (BGNE), Sarepta Therapeutics (SRPT), Mylan (MYL), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), Amarin (AMRN) and Forty Seven (FTSV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include Alibaba Group (BABA), AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Amarin (AMRN), Baidu (BIDU) and Roku (ROKU).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Capital International Investors (5.59%), Oracle Investment Management Inc. (3.68%), State Street Corp (3.66%), Capital World Investors (3.15%), Capital International Inc. CA (2.18%) and Eagle Asset Management Inc. (1.43%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View institutional ownership trends for Biohaven Pharmaceutical.

BHVN stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Oracle Investment Management Inc., Marshall Wace LLP, Eagle Asset Management Inc., Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., State Street Corp, and UBS Group AG. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, Kimberly Gentile, and Robert Berman. View insider buying and selling activity for Biohaven Pharmaceutical.

BHVN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Norges Bank, Point72 Asset Management L.P., Pictet Asset Management Ltd., Bluefin Trading LLC, Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric. View insider buying and selling activity for Biohaven Pharmaceutical.

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BHVN stock can currently be purchased for approximately $35.28.

Biohaven Pharmaceutical has a market capitalization of $2.06 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe. View additional information about Biohaven Pharmaceutical.

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.